Researchers unravel LacY web
An Anglo-US team of researchers has unveiled the first structure of
a membrane transport protein; disruptions in the activity of MTPs
are involved in a number of diseases.
Roche takes crystal-clear route to development
Swiss drugmaker Roche has succeeded in developing a crystalline
form of one of its pipeline compounds with the help of a US
company, TransForm Pharmaceuticals, that is applying a
high-throughput approach to form and formulation.
LIT spectrometer pushes back sensitivity barrier
A linear ion trap (LIT) spectrometer that is up to 10 times more
sensitive than current systems will be launched later this year by
Applied Biosystems/MDS SCIEX
Qiagen sales accelerate on new product lines
Qiagen has reported strong growth in sales and profits in the
second quarter as last year's acquisitions of GenoVision and
Xeragon start to exert their effects. The company has also signed
two new deals in the area of RNA interference.
Angiogenesis conference set for September
A conference examining the progress made in the field of
angiogenesis inhibition,organised by SRI, will take place 29-30
September in Cambridge, Massachusetts.
Pharmagene says profitability is a realistic objective
Pharmagene has reported a near-doubling in turnover in the first
half of this year, on the back of strong growth in its drug
discovery services division.
Dharmacon gets US RNAi patent
Dharmacon has been awarded a US Patent (No 6,590,093) which covers
its proprietary 2'-ACE chemistry for the production of synthetic
Takeda strikes deals to boost pipeline
Takeda signs two new research collaborations in the areas of
Alzheimer's disease and antibody-based drugs, in a move to bolster
its product pipeline.
GPC says anti-MHC antibody is nearing clinic
GPC reports progress with its anti-MHC class II antibody, with
potential in a range of haematological malignancies, and says it
now has sufficient quantities to start a clinical trials programme.
Pfizer pulls out of Phytopharm collaboration
Botanical drug specialist Phytopharm suffered a setback yesterday
when Pfizer withdrew from a collaboration to develop P57, a drug
for obesity and metabolic syndrome.
Gene silencing promise sparks IP rush
The battle to amass intellectual property in the hot area of RNA
interference (RNAi) continues to gain pace, with one of the key
players in the category, Alnylam Pharmaceuticals, licensing patents
from the UK's Cambridge Research...
siRNA library to benefit Abbott, and others
Dharmacon and Abbott Laboratories are to develop a
short-interfering RNA (siRNA) library covering 4,000 genes to help
identify potential drug targets.
Argonaut exits HPLC business
Argonaut sells its HPLC business to Grace Vydac as it refocuses on
supplying consumables for companies working on drug discovery.
Reports reduced losses in first half.
New skin cancer gene located
Cancer Research UK scientists have found the location of a new gene
on chromosome 1 which pre-disposes people to skin cancer.
GSK signs up for ACLARA's eTag system
GSK is the latest company to sign a license for ACLARA Biosciences'
eTag Assay System, used in gene expression profiling studies.